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A B S T R A C T
Current treatment for major depressive disorder (MDD), a prevalent and disabling mental illness, is
inadequate, with two-thirds of people treated with ﬁrst-line antidepressants not achieving remission.
MDD is for many a chronic condition, often requiring multiple treatment attempts, thus development of
additional interventions is urgently required. An emerging approach to improve non-response to
antidepressants is the use of adjunctive nutraceuticals. The pathophysiology of MDD is considered to
involve a range of abnormalities (monoamine impairment, neuro-endocrinological changes, reduced
brain-derived neurotrophic factor, and cytokine alterations). By targeting an array of these key
neurobiological pathways via speciﬁc nutraceuticals (S-adenosyl methionine; [SAMe], 5-HTP [active
tryptophan], folinic acid [active folic acid], omega-3 fatty acids, and zinc), there is the potential to
provide a more comprehensive therapeutic biological approach to treat depression. We are currently
conducting a National Health and Medical Research Council funded study in Australia (APP1048222).
The clinical trial is phase II/III, multi-site, 3-arm, 8-week, randomised, double-blind, placebo-controlled
study using SAMe + folinic [1_TD$DIFF]acid versus a combination nutraceutical (SAMe, 5-HTP, folinic acid, omega-3,
and zinc) or matching placebo in 300 currently depressed participants with diagnosed MDD who are
non-responsive to current antidepressants (ANZCTR, protocol number: 12613001300763). The results
may provide evidence for a novel adjunctive neurobiological approach for treating depression.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Major depressive disorder (MDD) is a prevalent and highly
disabling mental illness, causing marked occupational and social
impairment and reduced quality of life [1]. The National Health
Survey conducted by the Australia Bureau of Statistics in
2001 estimated that 4.7% of Australians had taken an antidepres-
sant medication for their mental wellbeing within the prior two* Corresponding author at: The Melbourne Clinic, Department of Psychiatry, The
University of Melbourne, 2 Salisbury Street, Richmond, Melbourne, Australia.
Tel.: +61 3 94209350.
E-mail address: jsarris@unimelb.edu.au (J. Sarris).
http://dx.doi.org/10.1016/j.aimed.2015.02.001
2212-9588/ 2015 Elsevier Ltd. All rights reserved.weeks [2]. Further to this, depressed mood is for many a chronic
condition, often requiringmultiple treatment trials [3]. Complicat-
ing this, is that efﬁcacy of established treatments are currently
modest at best. This is evidenced by the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) study, a multi-site,
prospective, randomised, multi-step clinical trial comparing a
series of adjunctive or alternative treatments for patients who did
not respond to the selective serotonin reuptake inhibitor (SSRI)
citalopram [4]. Results conﬁrmed that only a minority of people
with MDD achieve remission via initial treatment with an SSRI.
Switching, combining or augmenting produced beneﬁts to some
initial non-responders, however one third of people with MDD did
not achieve complete remission, even after multiple treatment
strategies. Furthermore, as revealed in a highly publicised
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effect size between antidepressants and placebo (d = 0.20) in
mildly ill patients. As current treatment is inadequate, develop-
ment of additional interventions is urgently required. An emerging
approach to improve non-response to antidepressants including
SSRIs is the use of adjunctive nutraceuticals.
The pathophysiology of MDD is considered to involve a range of
abnormalities such as monoamine impairment, neuro-endocrino-
logical changes, reduced brain-derived neurotrophic factor (BDNF),
and cytokine alterations (see Fig. 1) [6]. Use of adjunctive
nutraceuticals may improve the clinical effect of antidepressants
by addressing several key neurobiological mechanisms underpin-
ning the disorder. These nutraceuticals include: S-adenosyl
methionine (SAMe), 5-hydroxytryptophan (5-HTP), eicosapenta-
enoic acid (EPA), zinc, and folic acid (either folinic acid or 5-MTHF)
(Fig. 2).
1.1. S-Adenosyl methionine (SAMe)
SAMe is an endogenous sulphur-containing compound that is a
critical neurochemical component involved in the one-carbon
cycle responsible for the methylation of neurotransmitters that
regulate mood [7,8]. SAMe may improve depressed mood via
enhanced methylation of catecholamines and increased serotonin
turnover, reuptake inhibition of norepinephrine, enhanced dopa-
minergic activity, decreased prolactin secretion, and increased
phosphatidylcholine conversion [9]. Animal depression models
have also shown SAMe to restore the levels of putrescine in the
nucleus accumbens [10]; this polyamine being shown to have
antidepressant effects [11].
A recent site-based reanalysis of 144 patients from a failed
12-week 3-arm double-blind RCT [12] using SAMe monotherapy
(1600 mg/day) versus SSRI escitalopram (20 mg) and placebo in
adults with diagnosedMDD found a signiﬁcant difference between
SAMe from baseline to week 12 (p = 0.039) versus placebo [13]. At
the week 12 endpoint, remission rates on the Hamilton Depression
Rating Scale (HAM-D  7)were 34% for SAMe, 23% for escitalopram
and 6% for placebo, signiﬁcantly in favour of SAMe (p = 0.014).
SAMe was found to be superior to placebo from week 1, and to
escitalopram during weeks 2, 4, and 6. These results need to be
interpreted with caution, however, in view of the failed parent
study. In addition, a 6-week double-blind RCT by Papakostas et al.
[14] involving 73 MDD patients non-responsive to SSRIs found[(Fig._1)TD$FIG]
Fig. 1. Pathophysiology of depression and the nutraceuresponse (HAM–D  50% reduction) and remission rates were
signiﬁcantly higher for patients treated with adjunctive SAMe
(36.1% and 25.8%, respectively) than adjunctive placebo (17.6% vs.
11.7%, respectively).
1.2. 5-Hydroxytryptophan (5-HTP)
5-HTP is an essential monoamine precursor that is derived from
L-tryptophan, and is required for the synthesis of serotonin [15]. 5-
HTP and tryptophan have been studied as an antidepressant
[16]. Eight controlled adjunctive studies using L-tryptophan or 5-
HTP with antidepressants provide positive ﬁnding of augmenta-
tion effects in increasing the antidepressant response with
phenelzine sulphate, clomipramine, tranylcypromine, and ﬂuoxe-
tine. A systematic review and meta-analysis[16] on two studies
meeting criteria (pooled n = 64) suggest that 5-HTP and L-
tryptophan monotherapy are more effective than placebo at
alleviating depression (OR = 4.1, 95% CI = 1.3,13.2).
1.3. Omega-3 fatty acids
Omega-3 fatty acids have a critical role in neural function and
great potential for treating depression, especially if an inﬂamma-
tory causation is present [17,18]. The antidepressant activity of
omega-3 fatty acids appears to occur via modulation of norepi-
nephrine, dopamine and serotonin re-uptake, degradation, syn-
thesis and receptor binding; anti-inﬂammatory effects; and the
enhancement of cell membrane ﬂuidity [19].
A meta-analysis by Martins [20] found that eicosapentaenoic
acid (EPA) preparations, or those with higher EPA to docosahex-
aenoic acid (DHA) ratios, potentially have a stronger antidepres-
sant effect than DHA alone. The meta-analytic comparison
between DHA and EPA found that DHA monotherapy was not
signiﬁcant, whereas studies using supplements containing >50%
EPA had a signiﬁcant antidepressant effect (p = 0.0050). While
not all monotherapy studies are supportive of omega-3 fatty
acids for depression, it appears that strong evidence exists for
adjunctive use with SSRIs [21]. A 12-month double-blind RCT
used 460 mg EPA and 380 mg DHA in patients (n = 2081) with
post-myocardial infarction [22]. While no effects from EPA/DHA
supplementation over placebo were revealed on depressive
symptoms (Beck Depression Inventory II), in a sub-sample taking
conventional antidepressants, a signiﬁcant antidepressant effectticals modulating these neurochemical pathways.
[(Fig._2)TD$FIG]
Fig. 2. SAMe and other key nutraceuticals with antidepressant activity.
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[23] used 900 mg of EPA and 200 mg of DHA (or placebo)
adjunctively with citalopram in the treatment of MDD. The
combination therapy demonstrated signiﬁcantly greater im-
provement in HAM-D scores at study endpoint (p = 0.008).
1.4. Zinc
The mineral zinc is a divalent cation that is one of the most
prevalent trace elements in the amygdala, hippocampus, and
neocortex, and is involved with hippocampal neurogenesis via up-
regulation of BDNF, while also modifying N-methyl-D-aspartate
(NMDA) and glutamate activity [24,25]. A meta-analysis compar-
ing peripheral blood zinc concentrations between depressed and
non-depressed participants included 17 studies which revealed
zinc concentrations were approximately 1.85 micromol/L lower
in depressed participants compared to control subjects (CI 95%:
2.51 to 1.19 micromol/L, p < 0.00001) [26]. Greater depression
severity was associated with greater relative zinc deﬁciency.
There is emerging evidence for zinc in improving depressed
mood. A review by Lai et al. [27] aimed to synthesise results from
all published RCTs on the efﬁcacy of zinc supplementation for
reducing or preventing depressive symptoms. They found four
studies that met inclusion criteria. Two key 12-week RCTs that
examined the effects of zinc (25 mg/d) monotherapy supplemen-
tation as an adjunct to antidepressants found that zinc signiﬁcantly
lowered depressive symptom scores of depressed patients (pooled
standard mean difference over placebo on HAM-D of 2.84 points,
p < 0.001). Interestingly, sub-therapeutic doses of zinc have also
been shown in animal depression models to elicit a synergistic
effect in enhancing the antidepressant activity of several
antidepressants [28]. This combined evidence suggests potential
beneﬁts of zinc as a stand-alone intervention or as an adjunct to
conventional antidepressant drug therapy for depression. Amino
acid or picolinate forms are advised to be used due to improved
absorbability [29].
1.5. Folic acid (folinic acid)
Folate (nutraceutical form is folic acid) is involved with
methylation pathways in the one-carbon cycle, and is responsiblefor the metabolism and synthesis of various monoamines, and
most notably is involved with synthesis of SAMe from homocys-
teine [30]. Several studies have assessed the antidepressant effect
of folic acid with concomitant antidepressant use, with most
yielding positive results in enhancing either antidepressant
response rates, or increasing the onset of response. For example,
a study conducted by Coppen andBailey [31] used 500 mcg of folic
acid or placebo adjunctivelywith 20 mgﬂuoxetine in 127 subjects
with a HAM-D score of 20. There was a statistically signiﬁcant
reduction in depression scores after 10 weeks for women in the
ﬂuoxetine plus folic acid condition comparedwith ﬂuoxetine plus
placebo (p < 0.001; Cohen’s d = 0.73). A recent study by Papa-
kostas et al. [32] supported the 5-MTHF form (Deplin1) at 15 mg/
day as an adjunctive treatment for MDD. The activated forms
folinic acid or 5-methyltetrahydrofolate (5-MTHF) are recom-
mended as these are not affected by 5-MTHF reductase
polymorphisms [33].
1.6. Beneﬁts of studying a combination antidepressant nutraceutical
As the majority of MDD sufferers treated with ﬁrst-line
antidepressants do not achieve remission, safe and effective
adjunctive treatments that improve therapeutic response to
antidepressants are of potential beneﬁt. In view of the theoretical
foundations and favourable data of the antidepressant effect of
nutraceuticals such as SAMe, 5-HTP, EPA, zinc and folic acid, they
may serve as potential treatments for enhancing response of SSRIs
in patients with clinical depression. Given this rationale, we are
currently conducting an adjunctive double-blind RCT to conﬁrm
the efﬁcacy of SAMe and a combination nutraceutical for the
treatment of non-responsive antidepressant-medicated partici-
pants currently experiencing major depression.
2. Trial objectives
The objective of this trial is to measure the effectiveness and
safety of SAMe versus a combination nutraceutical (CN) as
adjunctive treatments to standard antidepressant medication for
MDD. We will also measure the relationship between treatment
response and changes in levels of key biomarkers (brain-derived
neurotrophic factor [BDNF], zinc, folate, B12, fatty acids and
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modiﬁed by single nucleotide polymorphisms (SNPs) in speciﬁc
genes involving methylation and monoamine pathways.
3. Hypotheses
The primary hypothesis:(1) Adjunctive SAMe will be superior to adjunctive placebo in the
treatment of MDD, while the adjunctive combination nutra-
ceutical (CN), will be superior to both SAMe and placebo, as
assessed by change in Montgomery–Asberg Depression Scale
(MADRS) scores after the 8-week treatment phase
Secondary hypotheses:(2) Self-rated depressed mood on the Beck Depression Inventory
(BDI-II), and general health questionnaire (Short Form Survey
12), will also be signiﬁcantly improved by both interventions
over placebo(3) SAMe and the CN will produce a signiﬁcant increase in serum
BDNF, and a signiﬁcant decrease in homocysteine compared to
placebo(4) Changes in outcome rating scaleswith a lessening of depressive
symptoms will correlate with increases in serum BDNF, and a
lowering of serum homocysteine in both groups, but not the
placebo(5) A greater therapeutic effect will occur in males compared to
females (as reﬂected in unpublished data [34]).
4. Trial design
4.1. Study design and plan
The design of the study is a phase II/III, multi-site, 3-arm, 8-
week, randomised, double-blind, placebo-controlled trial using
SAMe, a combination nutraceutical (SAMe + 5-HTP, folic acid in
folinic form, EPA and zinc) or matching placebo in 300 currently
depressed participants with MDD who are non-responsive to their
current antidepressant medication (SSRI, SNRI, NaRI, tetracyclic or
5-HT2c antagonist). The trial sites are at TheMelbourne Clinic (The
University of Melbourne), Richmond, Melbourne, Australia; and
The Royal Brisbane and Women’s Hospital (The University ofTable 1
Single Nucleotide Polymorphism (SNP) list.
dbSNP ID Alternative ID Gene sym
rs4680 Val158Met COMT
rs1801133 C677T MTHFR
rs1801131 A1298C MTHFR
rs1799913 A779C TPH1
rs1800532 A218C TPH1
rs25531 – SLC6A4
rs13107325 – SLC39A8
rs10764176 – SLC39A12
rs174561 – FADS1
rs174589 – FADS2
rs164575 – FADS2
rs234706 C699T CBS
rs3733890 716G4A BHMT
rs1805087 Asp919Gly MTR
rs1801198 Pro259Arg TCN2
rs1045642 C3435T ABCB1
Other polymorphisms
5HTTLPR SLC6A4
STin2 VNTR SLC6A4
845ins68 68bp dup CBSQueensland), Herston, Brisbane, Australia. Recruitment is currently
occurring from September 2013 and is planned to occur until
September 2016.
Participants will be required to attend ﬁve visits at the study
site atweek 0 (baseline), 2, 4, 6 and 8, aswell as a safety assessment
over the phone at week 1. At the baseline visit, participants will be
asked to complete consent forms, screening assessments, and
mood and anxiety questionnaires. All eligible participants will be
randomly allocated to a treatment arm, and corresponding
treatment will be provided. All subsequent visits will follow the
same outline of the baseline session excluding consent forms and
screening assessments and including a safety assessment. In
addition, participants will be required to provide a blood sample at
baseline and prior to the week 8 visit. To compensate for their time
and travel expenses, participants will be given $50 at the week
2 visit and another $50 at the ﬁnal week 8 visit. On completion they
will also be given two months’ supply of SAMe tablets. This study
has ethical clearance (TMC_HREC 220, UQ_MREC 2013000199),
and is registered on ANZCTR (protocol number: 12613001300763).
The study is funded by an Australian National Health and Medical
Research Council project grant (APP1048222), and is co-sponsored
by Bioceuticals.
It should be noted that we are also conducting a monotherapy
version of the study for participants not taking antidepressant
medication, presenting with mild-moderate depression (MADRS
14-25). The design of the study is nearly identical (ANZCTR
protocol number: 12613001299796, TMC_HREC 232, UQ_M-
REC_2014000702), however this paper focuses on the main
adjunctive study protocol.
4.2. Outcome measures SboAFER 2.0 criteria (for assessing suitability for study entry)
 MINI_version 6.0 (for assessing diagnosis)
 Mood measured via Montgomery–Asberg Depression Rating
Scale (MADRS) [clinician-assessed primary outcome] and Beck
Depression Inventory (BDI-II) Anxiety measured using the Hamilton Anxiety Rating Scale
(HAMA) Health-related quality of life measured using the Short Form
Survey-12 (SF-12) Sleep measured using the Leeds Sleep Evaluation Questionnaire
(LSEQ)l Gene name
Catechol-o-methyltransferase
Methylenetetrahydrofolate reductase
Methylenetetrahydrofolate reductase
Tryptophan hydroxylase 1
Tryptophan hydroxylase 1
Serotonin transporter
Zinc transporter
Zinc transporter
Fatty acid desaturase 1
Fatty acid desaturase 2
Fatty acid desaturase 2
Cystathionine b-synthase
Betaine homocysteine methyltransferase
Methionine synthase
Transcobalamin-II
P-glycoprotein
Serotonin transporter
Serotonin transporter
Cystathionine b-synthase
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ence Scale (ASEX) Psychomotor symptoms of depression measured using the CORE
Assessment of Psychomotor Change Global rating of illness severity and improvement measured
using the Clinical Global Impression (CGI) severity (CGI-S) and
improvement (CGI-I) scales SAFTEE (for assessment of adverse reactions)
 Single nucleotide polymorphisms (SNPs) in speciﬁc genes
involved in methylation and monoamine pathways measured
via blood sample at baseline (Table 1) Levels of brain-derived neurotrophic factor (BDNF), zinc, folate,
B12, fatty acids and homocysteine measured by obtaining blood
samplesInclusion criteria:
 Aged 18–70 years
 Currently taking an SSRI, SNRI, NaRI, tetracyclic or 5-HT2c
antagonist, (or bupropion) for a minimum of four weeks, and
on a stable dose for a minimum of two weeks.
 Fulﬁls the DSM-IV and DSM-V diagnostic criteria for Major
Depressive Disorder (for DSM-IV-TR diagnosis this is based on
the Mini International Neuropsychiatric Interview 6.0 [MINI
6.0]. We will switch to DSM-V sole diagnosis and will use the
corresponding version of the MINI when available)
 Presents with moderate to severe depression (MADRS  18)
at time of study entry
 Meets SAFER 2.0 criteria for participation in a clinical trial
 Fluent in written and spoken English
 Has the capacity to consent to the study and follow its
procedures1 The SAMe is provided in tablet form (blister pack sealed, and stored in
refrigeration at 4–8 8C). The Combination Formula is provided in soft-gel capsules
and stored at room temperature 15–25 8C.Exclusion criteria:
 Currently taking MAOIs (reversible or non-reversible) or
tricyclic antidepressant
 Current use of speciﬁed nutraceuticals, e.g. St John’s wort,
SAMe, 5-HTP at any dose or folic acid >500 mcg per day,
omega-3 >180 mg EPA per day, zinc>10 mg per day (in such
cases a one week washout can be employed before
rescreening and potential inclusion)
 Presents with suicidal ideation (>3 on MADRS suicidal
thoughts domain) at the time of study entry
 Three or more failed trials of pharmacotherapy or somatic
therapy (e.g. electroconvulsive therapy) for the current major
depressive episode
 Meets DSM-IV diagnostic criteria for bipolar disorder I/II or
presence of psychosis on structured interview (MINI 6.0)
 A primary clinical diagnosis of a substance/alcohol use
disorder within the last 12 months on structured interview
(MINI 6.0)
 Recently commenced psychotherapy (>4 weeks of stable
treatment acceptable) Taking warfarin or phenytoin
 Known or suspected clinically unstable systemic medical
disorder (including cancer, organ failure, or serious cardio/
cerebrovascular disease)
 Pregnancy or breastfeeding
 Not currently using medically approved contraception
(including abstinence) if female and of childbearing age
 Allergy or intolerance to seafood or taking nutraceuticals4.3. Treatment interventions
Participants are randomly assigned via computerised number
generation (3  3 blocks) to Group A (SAMe), Group B (combina-
tion nutraceutical) or Group C (placebo). An independent
researcher conducted the randomisation, while trial researchers
and investigators are blinded as to which groups the participants
will be assigned to (as are the participants themselves).
All participants are required to take 2 tablets and 2 capsules
twice per day for 8 weeks.
Group A (SAMe)1 SAMe (800 mg/day)
 Folinic acid (500 mcg/day)
 Co-factor vitamin B12 (200 mcg/day) to assist in the conversion
of homocysteine to SAMe [plus inactive placebo capsules]
Group B (combination nutraceutical)1 SAMe (800 mg/day)
 Folinic acid (500 mcg/day)
 Co-factor vitamin B12 (200 mcg/day) to assist in the conversion
of homocysteine to SAMe PLUS
 Omega-3 fatty acid concentrate (EPA-esters 1000 mg/day, DHA-
esters 656 mg/day) 5-HTP (200 mg/day)
 Zinc picolinate (30 mg elemental/day)
 Co-factors vitamin B6 (100 mg/day), vitamin C (60 mg/day), and
magnesium (amino acid chelate, elemental 40 mg/day) to assist
in the conversion of 5-HTP to serotonin Cofactor vitamin E (40 IU/day) to stabilise the omega 3
Group C (matching placebo) SAMe placebo matching tablets and CN placebo matching
capsules (1% ﬁsh oil is added to the placebo capsules to assist
with blinding)
4.4. Statistical analyses
Analysis of data will be conducted with blinding to group
allocations. Linear mixed models will be used to determine
differences in MADRS depressive symptom severity over the study
period by group allocation. The mixed models approach enables
use of all repeated measurements, accounts for clustering of
participants within recruitment sites, and provides unbiased
estimates in the presence of missing data. Potential covariates
will be assessed for their association with group allocation and
MADRS depressive symptom severity using chi-square, Fisher’s
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structure. Non-parametric statistics will be used when assump-
tions for parametricmethods are violated. Covariates with p values
0.10 will be retained for adjusted analysis. Unadjusted models
will included ﬁxed effects of time, group, and a time  group
interaction term as well as random effects of individual,
recruitment site, intercept and time. Adjusted models will include
relevant covariates as well as covariate  time and covariate x
group interaction terms. We will analyse data from SAMe versus
the CN group and placebo (whole study analysis) AND also SAMe
versus placebo and CN versus placebo (as two independent
studies). Outlier data that is over 3 standard deviations of the
sample mean will be removed. All tests of treatment effects will be
conducted using a two-sided alpha level of 0.05 and 95%
conﬁdence intervals and Cohen’s d effect sizes will be calculated
were appropriate.Modellingwill be performed using the Statistical
Package for Social Sciences software (SPSS, version 22.0, IBM,
Chicago, IL, USA).
4.5. Power analysis
We aim to recruit a sample size of 300 participants (100 parti-
cipants in each arm), with a projected loss of 15–20% based on our
previous RCTs. The study is powered to detect a potential small to
moderate difference between the SAMe and CN groups (using all
data via intention-to-treat analysis). Based on a two tailed analysis
with a = 0.05, b = 0.80, and a critical F2,298 of 3.02, 300 participants
are required to detect a difference in MADRS scale score between
SAMe, CN and placebo groups (Cohen’s d effect size of 0.36 or
greater). The sample size of 100 per arm is sufﬁciently powered to
provide statistical difference between the SAMe and placebo
groups.
5. Discussion
The nutraceuticals studied have the potential to show signiﬁ-
cant beneﬁts in ameliorating depression in people non-responsive
to contemporary antidepressants. SAMe and an enhanced SAMe
combination nutraceutical formula offers a potentially affordable,
safe, and effective treatment option. Further, understanding the
biological modifying factors affecting response may allow for
future judicious clinical application of these interventions. A
positive ﬁnding will have the signiﬁcant impact of clinicians and
the public being offered an ‘‘evidence-based’’ approach to
enhancing antidepressant response, and improving depression
treatment.[(Fig._3)TD$FIG]
Fig. 3. Clinical triOne potential deﬁcit of common nutraceutical research is the
use of isolated nutrients as opposed to multi-component formulas.
While it is appreciated that modern scientiﬁc paradigm mandates
the study of isolated interventions to avoid the confound of
multiple interventions providing no understanding of which
components are effective, this approach may not be beneﬁcial in
studying nutrient-based nutraceuticals. Nutrients commonlywork
in concert [35] and as detailed above, a range of nutraceuticals
modulate several key pathways involved with the pathogenesis of
depression. As discussed, the current reductive approach to
depression treatment may also be suboptimal, with several
neurobiological pathways implicated in the disorder; yet medici-
nal approaches (and clinical trials) usually focus on modulating
just one or two neurochemicals. While it may not be clear as to
which nutrient components may be responsible for any found
effect, it should be noted that each component in our presently
studied formula has underpinning antidepressant evidence.
Additionally, it is important to utilise co-factors involved in the
metabolism of the key nutrients e.g. folinic acid for SAMe in the
one-carbon cycle, and zinc, magnesium, vitamin C, and B6 for 5-
HTP conversion to serotonin [36]. Our design has taken this into
account and has incorporated these co-factors into the formulation
(Fig. 3).
While it may be argued that a statistically signiﬁcant effect
between treatments and placebo is the goal of any study, the real
goal of our study is to provide ‘‘clinically’’ signiﬁcant from the CN
group for antidepressant activity beyond that of what would be
expected as occurring from the individual components alone e.g.
SAMe. This would equate to an estimated differential reduction
over placebo of over 6 points on the MADRS, being beyond the
normal signiﬁcant reduction of 3–4 points on the MADRS found on
average in studies (sample sizes 80–150). In other words, if little
difference occurred between SAMe and the CN, then there would
be little point in broadly advising its use due to increased cost
above SAMe or other individual evidence-based components such
as EPA. Further analysis of the data however may still ﬁnd
individual characteristics for thosewho respond to the CN formula.
In respect to general safety application of the combination
formulation, all the major key nutrients are being used in
therapeutic doses and all have good safety proﬁles. Regardless,
SAMe use should be monitored for the unlikely event of switching
in bipolar disorder; 5-HTP use while potentially enhancing
serotonin levels should be observed closely if used in concert
with antidepressants due to serotonin syndrome (of more
potential concern in higher doses); Zinc should not be used
beyond a therapeutic dose due to potentially unbalancing mineralal ﬂowchart.
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5-MTHF or folinic acid; Omega-3 fatty acids should present with
little safety issues, however higher doses may interact with anti-
coagulants. In our study, participants are rigorously monitored for
any adverse effects, and these will be documented in the future
published results.
In summary, it is intended that our study, positive results
permitting, may provide a needed potential treatment option to
enhance the efﬁcacy of antidepressants. This may have signiﬁcant
clinical beneﬁts, and may encourage the study of more complex
nutraceutical formulations for other medical disorders.
Conﬂicts of interest
JS has received honoraria, research support, royalties, or
consultancy or travel grant funding from Integria Health, Black-
mores, Bioceuticals, Taki Mai, Pepsico, HealthEd, Soho-Flordis,
Pﬁzer, Elsevier, the Society forMedicinal Plant and Natural Product
Research, CR Roper Fellowship, The NHMRC. DM has received
research support from the Bowman Family Foundation, Fish-
erWallace, Ganeden, Nordic Naturals, Methylation Sciences, Inc.
(MSI), and PharmoRx Therapeutics. He has received honoraria for
consulting, speaking, and writing from the Massachusetts General
Hospital Psychiatry Academy. He has received royalties from
Lippincott Williams & Wilkins for published book ‘‘Natural
Medications for Psychiatric Disorders: Considering the Alterna-
tives.’’ CS has received research grants from Government:
Australian Research Council; NHMRC; NDLERF; NIDA; VDLERF;
ARC; Vicpolice; Vicroads; Nestle; SFI; Barry Callebaut; Blackmores;
Flordis; Zeller; Clover Corporation; Horphag; GSK; Bayer; Phar-
malink; Siemens; Securatek; Efamol; Cognis; Integria; Medvet,
Cooper Nutrition, and paid strategic consulting advice for SFI,
Blackmores, Bayer; ARU, Carlton FC, GSK India. No other speciﬁc
conﬂicts identiﬁed.
Acknowledgments
This grant is funded by a National Health and Medical Research
Council project grant (APP1048222), and is co-sponsored by
Bioceuticals. Dr Jerome Sarris is supported by a CR Roper
Fellowship. Michael Berk is supported by a NHMRC Senior
Principal Research Fellowship (1059660). Chad Bousman is
supported by a Ronald Phillip Grifﬁth Fellowship.
References
[1] Donohue J, Pincus H. Reducing the societal burden of depression: a review of
economic costs. Quality of care and effects of treatment. PharmacoEconomics
2007;25(1):7–24.
[2] AIHW. Mental health services in Australia 2001-02. Canberra: AIHW; 2004.
[3] Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The
STAR*D study: treating depression in the real world. Cleve Clin J Med
2008;75(1):57–66.
[4] Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al.
Background and rationale for the sequenced treatment alternatives to relieve
depression (STAR*D) study. Psychiatric Clin N Am 2003;26(2):457–94. x.
[5] Fournier J, DeRubeis R, Hollon S, Dimidjian S, Amsterdam J, Shelton R, et al.
Antidepressant drug effects and depression severity: a patient-level meta-
analysis. JAMA 2010;303(1):47–53.
[6] Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358(1):
55–68.
[7] Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe)
as treatment for depression: a systematic review. Clin Invest Med
2005;28(3):132–9.
[8] Baek J, Bernstein E, Nierenberg A. One-carbon metabolism and bipolar disor-
der. Aust N Z J Psychiatry 2013;47(11):1013–8.
[9] Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treat-
ment of major depressive disorder. J Clin Psychiatry 2009;70(Suppl. 5):18–22.[10] Genedani S, Saltini S, Benelli A, Filaferro M, Bertolini A. Inﬂuence of SAMe on
the modiﬁcations of brain polyamine levels in an animal model of depression.
NeuroReport 2001;12(18):3939–42.
[11] Zomkowski AD, Santos AR, Rodrigues AL. Putrescine produces antidepressant-
like effects in the forced swimming test and in the tail suspension test in mice.
Prog Neuropsychopharmacol Biol Psychiatry 2006;30(8):1419–25.
[12] Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, et al. A
Double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-
methionine (SAMe) versus escitalopram in major depressive disorder. J Clin
Psychiatry 2014;75:370–6.
[13] Sarris J, Papakostas G, Vitolo O, Fava M, Mischoulon D. S-Adenosyl methionine
(SAMe) versus escitalopram and placebo in major depression: efﬁcacy and
effects of histamine and carnitine as moderators of response. J Affect Disord
2014; [2_TD$DIFF]164:76–81.
[14] Papakostas GI, Mischoulon D, Shyu I, Alpert JE, FavaM. S-adenosyl methionine
(SAMe) augmentation of serotonin reuptake inhibitors for antidepressant
nonresponders with major depressive disorder: a double-blind, randomized
clinical trial. Afr J Psychiatry 2010;167(8):942–8.
[15] ByerleyWF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review
of its antidepressant efﬁcacy and adverse effects. J Clin Psychopharmacol
1987;7(3):127–37.
[16] Shaw K, Turner J, Del Mar C. Are tryptophan and 5-hydroxytryptophan
effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry
2002;36(4):488–91.
[17] Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inﬂammation and
the pathogenesis of depression. Trends Immunol 2006;27(1):24–31.
[18] Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the
brain. Asia Pac J Clin Nutr 2008;17(Suppl 1):220–8.
[19] Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-
analyses of use in mania and bipolar depression. J Clin Psychiatry
2012;73(1):81–6.
[20] Martins JG. EPA but not DHA appears to be responsible for the efﬁcacy of
omega-3 long chain polyunsaturated fatty acid supplementation in depres-
sion: evidence from a meta-analysis of randomized controlled trials. J Am Coll
Nutr 2009;28(5):525–42.
[21] Sarris J, Schoendorfer N, Kavanagh DJ. Major depressive disorder and nutri-
tional medicine: a review of monotherapies and adjuvant treatments. Nutr
Rev 2009;67(3):125–31.
[22] Zimmer R, Riemer T, Rauch B, Schneider S, Schiele R, Gohlke H, et al. Effects of
1-year treatment with highly puriﬁed omega-3 fatty acids on depression after
myocardial infarction: results from the OMEGA trial. J Clin Psychiatry
2013;74(11):e1037–45.
[23] Gertsik L, Poland RE, Bresee C, RapaportMH. Omega-3 fatty acid augmentation
of citalopram treatment for patients with major depressive disorder. J Clin
Psychopharmacol 2011;32:61–4.
[24] Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative
inﬂammatory pathways in depression. Prog Neuropsychopharmacol Biol Psy-
chiatry 2011;35(3):693–701.
[25] SwardfagerW, HerrmannN,McIntyre RS, MazereeuwG, Goldberger K, Cha DS,
et al. Potential roles of zinc in the pathophysiology and treatment of major
depressive disorder. Neurosci Biobehav Rev 2013;37(5):911–29.
[26] Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T,
Lanctot KL. Zinc in depression: a meta-analysis. Biol Psychiatry
2013;74(12):872–8.
[27] Lai J, Moxey A, Nowak G, Vashum K, Bailey K, McEvoy M. The efﬁcacy of zinc
supplementation in depression: systematic review of randomised controlled
trials. J Affect Disord 2012;136(1–2):e31–9.
[28] Cunha MP, Machado DG, Bettio LE, Capra JC, Rodrigues AL. Interaction of zinc
with antidepressants in the tail suspension test. Prog Neuropsychopharmacol
Biol Psychiatry 2008;32(8):1913–20.
[29] Barrie SA, Wright JV, Pizzorno JE, Kutter E, Barron PC. Comparative absorption
of zinc picolinate, zinc citrate and zinc gluconate in humans. Agents Actions
1987;21(1–2):223–8.
[30] Fava M, Mischoulon D. Folate in depression: efﬁcacy, safety, differences in
formulations, and clinical issues. J Clin Psychiatry 2009;70(Suppl 5):12–7.
[31] Coppen A, Bailey J. Enhancement of the antidepressant action of ﬂuoxetine by
folic acid: a randomised, placebo controlled trial. J Affect Disord 2000;60(2):
121–30.
[32] Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. L-
methylfolate as adjunctive therapy for SSRI-resistant major depression:
results of two randomized, double-blind, parallel-sequential trials. Am J
Psychiatry 2012;169(12):1267–74.
[33] Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are
not the same thing. Xenobiotica 2014;44(5):480–8.
[34] Sarris JPL, Carpenter L, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M,
Mischoulon D. Is S-adenosyl methionine (SAMe) for depression only effective
in males? A re-analysis of data from a randomized clinical trial. 2015 [submit-
ted for publication].
[35] Jacobs DJ, Tapsell L. Food, not nutrients, is the fundamental unit in nutrition.
Nutrition reviews. 2007;65(10):439–50.
[36] Osiecki H. The physician’s handbook of clinical nutrition. 7th ed. Brisbane:
Bioconcepts Publishing; 2006.
